Abstract
The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Pharmacokinetics of Biologic Agents
Volume: 9 Issue: 1
Author(s): Turhan Dost
Affiliation:
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Abstract: The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Export Options
About this article
Cite this article as:
Dost Turhan, The Pharmacokinetics of Biologic Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711700
DOI https://dx.doi.org/10.2174/187152310790711700 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics Dry Eyes in Rheumatic Disease
Current Rheumatology Reviews Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry The Genetic Variants of IKZF1 Gene Linked with the Growing Risk of Childhood Acute Lymphoblastic Leukaemia
Current Molecular Medicine Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Differentiation of Glioblastoma and Lymphoma Using Feature Extraction and Support Vector Machine
CNS & Neurological Disorders - Drug Targets Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery New Strategies for Therapeutic Cancer Vaccines
Anti-Cancer Agents in Medicinal Chemistry Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued)